截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 91,150,340 | | | RMB | | 91,150,340 | | 本月底結存 | | | 478,226,490 | RMB | | 1 RMB | | 478,226,490 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | -- ...

主力资金净流出的行业有23个，非银金融行业主力资金净流出规模居首，全天净流出资金80.79亿元， 其次是计算机行业，净流出资金为70.10亿元，净流出资金较多的还有电力设备、汽车、国防军工等行 业。 医药生物行业今日上涨2.79%，全天主力资金净流入34.75亿元，该行业所属的个股共474只，今日上涨 的有373只，涨停的有14只；下跌的有98只，跌停的有1只。以资金流向数据进行统计，该行业资金净流 入的个股有216只，其中，净流入资金超亿元的有16只，净流入资金居首的是药明康德，今日净流入资 金10.40亿元，紧随其后的是长春高新、恒瑞医药，净流入资金分别为5.99亿元、5.24亿元。医药生物行 业资金净流出个股中，资金净流出超亿元的有7只，净流出资金居前的有博瑞医药、爱尔眼科、美年健 康，净流出资金分别为2.11亿元、1.86亿元、1.82亿元。（数据宝） 医药生物行业资金流入榜 沪指9月1日上涨0.46%，申万所属行业中，今日上涨的有24个，涨幅居前的行业为通信、综合，涨幅分 别为5.22%、4.27%。医药生物行业今日上涨2.79%。跌幅居前的行业为非银金融、银行，跌幅分别为 1.28%、1.03%。 ...

Group 1 - The CRO concept index increased by 2.88%, ranking 8th among concept sectors, with 56 stocks rising, including Baohua Pharmaceutical, Dezhan Health, and ST Weiming hitting the daily limit [1][2] - Notable gainers in the CRO sector included Yiqiao Shenzhou, Puris, and Baicheng Pharmaceutical, which rose by 10.65%, 8.59%, and 8.46% respectively [1][2] - The sector saw a net inflow of 1.876 billion yuan, with 39 stocks receiving net inflows, and 7 stocks attracting over 50 million yuan [2][3] Group 2 - The leading stock in terms of net inflow was WuXi AppTec, with a net inflow of 1.04 billion yuan, followed by Fosun Pharma, Dezhan Health, and Chengdu Xian Dao with net inflows of 233 million yuan, 126 million yuan, and 93.8 million yuan respectively [2][3] - The highest net inflow ratios were observed in Dezhan Health, ST Weiming, and Baohua Pharmaceutical, with ratios of 26.23%, 17.45%, and 16.34% respectively [3][4] - The trading volume and turnover rates for key stocks in the CRO sector showed significant activity, with WuXi AppTec having a turnover rate of 4.09% and a price increase of 8.02% [3][4]

Group 1 - The CRO concept sector increased by 2.88%, ranking 8th among concept sectors, with 56 stocks rising, including Baohua Pharmaceutical, Dezhan Health, and ST Unimed hitting the daily limit [1] - Notable gainers in the CRO sector included Yiqiao Shenzhou, Puris, and Baicheng Pharmaceutical, which rose by 10.65%, 8.59%, and 8.46% respectively [1] - The sector saw a net inflow of 1.876 billion yuan, with 39 stocks receiving net inflows, and 7 stocks exceeding 50 million yuan in net inflow, led by WuXi AppTec with 1.04 billion yuan [2][3] Group 2 - The top stocks by net inflow ratio included Dezhan Health, ST Unimed, and Baohua Pharmaceutical, with net inflow ratios of 26.23%, 17.45%, and 16.34% respectively [3] - The top stocks in the CRO concept by net inflow included WuXi AppTec, Fosun Pharma, and Dezhan Health, with net inflows of 1.04 billion yuan, 233.4 million yuan, and 126.1 million yuan respectively [3][4] - Stocks with significant declines included Sichuan Shuangma, ST Biology, and Hitec Biotech, which fell by 3.73%, 3.03%, and 2.67% respectively [1][6]

沪指9月1日上涨0.46%，申万所属行业中，今日上涨的有24个，涨幅居前的行业为通信、综合，涨幅分别为5.22%、4.27%。医药生物行业今日上涨2.79%。跌幅居前的行业为非银金融、银行 资金面上看，两市主力资金全天净流出513.00亿元，今日有8个行业主力资金净流入，医药生物行业主力资金净流入规模居首，该行业今日上涨2.79%，全天净流入资金34.75亿元，其次是通信 主力资金净流出的行业有23个，非银金融行业主力资金净流出规模居首，全天净流出资金80.79亿元，其次是计算机行业，净流出资金为70.10亿元，净流出资金较多的还有电力设备、汽车、国 医药生物行业今日上涨2.79%，全天主力资金净流入34.75亿元，该行业所属的个股共474只，今日上涨的有373只，涨停的有14只；下跌的有98只，跌停的有1只。以资金流向数据进行统计， 医药生物行业资金流入榜 医药生物行业资金流出榜 ...

Market Overview - On September 1, the medical services sector rose by 3.84%, with Yingkang Life leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Services - Yingkang Life (300143) closed at 12.00, up 12.78% with a trading volume of 544,600 shares and a transaction value of 639 million [1] - Zihua Medicine (600721) closed at 9.85, up 10.06% with a trading volume of 562,700 shares [1] - Innovation Medical (002173) closed at 25.19, up 10.00% with a trading volume of 1,271,700 shares and a transaction value of 3.071 billion [1] - Other notable gainers include Puwis (301257), Baicheng Medicine (301096), and WuXi AppTec (603259) with respective increases of 8.59%, 8.46%, and 8.02% [1] Market Capital Flow - The medical services sector saw a net inflow of 1.699 billion in main funds, while retail funds experienced a net outflow of 1.134 billion [2] - The main funds showed a positive trend in several stocks, particularly WuXi AppTec with a net inflow of 1.087 billion [3] Individual Stock Performance - WuXi AppTec (603259) had a main fund net inflow of 1.087 billion, while retail funds saw a net outflow of 660 million [3] - Innovation Medical (002173) experienced a main fund net inflow of 405 million, with retail funds showing a net outflow of 240 million [3] - Sanbo Brain Science (301293) had a main fund net inflow of 152 million, while retail funds saw a net outflow of 107 million [3]

Group 1 - The core viewpoint highlights a significant upward trend in the medical sector, with major players like WuXi AppTec and United Imaging Healthcare experiencing substantial gains of over 7% and 6% respectively, alongside a notable increase in trading volume for the largest medical ETF in A-shares [1][3] - The medical ETF (512170) has shown a year-to-date increase of over 20%, indicating a strong recovery in the medical sector, yet it remains approximately 60% below its historical peak from 2021, suggesting considerable potential for further gains [3][4] - The current price-to-earnings (PE) ratio for the medical ETF's underlying index is around 36 times, which is still lower than 60% of the time over the past decade, indicating a favorable cost-performance ratio for investors [3][4] Group 2 - The ongoing bull market trend in A-shares presents an opportunity for low-valuation sectors like healthcare to experience a rebound, making it a focal point for investors [4][6] - The medical sector, particularly the medical ETF (512170) and its linked fund (012323), is emphasized as a key investment tool, focusing on medical devices (52%) and medical services (40%), which are closely related to AI healthcare [6][7] - The pharmaceutical sector is also highlighted, with a recommendation to consider the only pharmaceutical ETF (562050) and its linked fund (024986), which focuses on the top 50 pharmaceutical companies in A-shares, emphasizing innovative drugs (60%) while excluding medical and CXO sectors [7]

Group 1 - Pharmaceutical stocks in Hong Kong have shown strong performance, with notable gains in companies such as 加科思-B (up 23.18%), 三叶草生物-B (up 22.09%), and others [1] - The overall performance of Hong Kong pharmaceutical companies in the first half of the year has been robust, with 恒瑞医药 achieving record high revenue and profit, and 翰森制药 exceeding revenue expectations [1] - Upcoming major conferences, including the World Lung Cancer Conference (WCLC) and the European Society for Medical Oncology (ESMO), will showcase research results from innovative domestic drugs [1] Group 2 - 海通国际 maintains a positive outlook on Hong Kong pharmaceutical companies due to their stable cash flow, rich R&D pipelines, and normalizing external licensing revenues [2] - The recent slight pullback in the Hong Kong pharmaceutical sector is attributed to rapid fund rotation, with expectations of short-term fluctuations [2] - The long-term value reassessment logic in the pharmaceutical industry remains unchanged, supported by the engineer dividend and a rich catalyst environment in the innovative drug industry [2]

Core Viewpoint - The healthcare sector is showing signs of recovery after a period of adjustment, driven by policy support and technological advancements, with innovative drugs and high-end medical equipment leading the growth [1][4]. Group 1: Market Performance - As of September 1, 2025, the healthcare ETF Taikang (159760) rose by 2.35%, with a trading volume of 2.7428 million yuan [1]. - The index tracking the National Certificate Public Health and Healthcare Index (980016) increased by 2.54%, with significant gains in constituent stocks such as Changchun High-tech (000661) up 10.00%, and Health元 (600380) up 9.98% [1]. - The healthcare industry is experiencing a "first suppressed, then rising" trend, with signs of bottoming out since the second quarter of 2025 [1]. Group 2: Policy and Innovation - The State Council approved the "Biopharmaceutical Full Industry Chain Open Innovation Development Plan" on August 18, 2025, promoting innovation across all stages from approval to production [2]. - The drug regulatory authority is accelerating the establishment of review centers, reducing the approval cycle for innovative drugs and devices to 30 working days, enhancing market entry efficiency [2]. - The shift in procurement policy from "lowest price" to "quality + reasonable price" has alleviated profit pressures on companies [2]. Group 3: Company Performance - Major companies like Heng Rui Medicine reported innovative drug and licensing revenues of 9.561 billion yuan, accounting for 60.66% of total revenue, and secured a $12 billion collaboration with GSK [3]. - Mindray Medical's AI devices saw a 35% increase in installation in overseas high-end markets [3]. - WuXi AppTec's TIDES business revenue surged by 141.6% year-on-year, with a 48.8% increase in orders on hand [3]. Group 4: Future Outlook - The healthcare sector is emerging from a two-year adjustment period, with innovative drugs and high-end equipment leading the charge [4]. - The healthcare ETF (159828) serves as a comprehensive investment tool, allowing investors to capitalize on structural opportunities arising from the industry's recovery [4]. - Upcoming catalysts include overseas licensing progress for innovative drug companies and clinical data disclosures at the World Lung Cancer Conference, which may further bolster market confidence [4].

Group 1 - CRO concept stocks have shown significant gains, with WuXi AppTec (603259) up 6.3% at HKD 114.7, WuXi Biologics (02269) up 6.02% at HKD 35.2, and others like Kanglong Chemical (300759) and Kelaiying (002821) also experiencing notable increases [1] - Dongwu Securities reports that 22 CXO listed companies are expected to see revenue, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses grow by 14.16%, 64.03%, and 24.82% year-on-year for the first half of 2025, respectively [1] - The second quarter of 2025 is projected to show further improvement in revenue and profit growth rates, with expected increases of 15.15% in revenue and 53.58% in net profit attributable to shareholders [1] Group 2 - Xiangcai Securities highlights the active performance of the innovative drug industry chain under the backdrop of national encouragement for innovation, despite ongoing pressures from medical insurance cost control [2] - The establishment of a multi-tiered payment system and the rigid demand for medical services are expected to stabilize and rebound the industry [2] - Companies in the pharmaceutical outsourcing services sector, particularly in ADC CDMO and peptide CDMO for weight loss drugs, are recommended for attention, including WuXi AppTec, Haoyuan Pharmaceutical, and WuXi Biologics [2]